Natco Pharma Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 25, 2025
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma held its 42nd AGM on September 25, 2025, via video conference from its registered office in Hyderabad, with 62 members participating. Eight business items were taken up, including approval of FY25 financial statements, confirmation of three interim dividends totalling ₹6.00 per share for FY25, and re-appointment of Vice Chairman & CEO Rajeev Nannapaneni as a director retiring by rotation. Special business items included appointment of Secretarial Auditors, ratification of Cost Auditor remuneration, renewal of borrowing powers and charge creation limits under Sections 180(1)(c) and 180(1)(a), and a proposal to increase the company's Authorised Share Capital. The Statutory Auditors' report was unqualified with no adverse observations. Voting results from remote e-voting and AGM e-voting were to be announced within two working days.
The ₹6 per share total dividend confirmation is a positive signal for income-focused shareholders, while the proposal to raise Authorised Share Capital signals potential future fundraising or stock-based action. Borrowing power and charge creation renewals give the company flexibility for future debt, which could support expansion but also increase leverage.